Company Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies across the United States, Europe, Germany, Asia, and international markets, providing specialized treatments for multiple sclerosis, spinal muscular atrophy, and Friedreich's ataxia. The company operates within the healthcare sector, specifically classified under the industry of drug manufacturers - general, which signifies its role in creating essential pharmaceutical products for treating serious neurological conditions. This entity maintains a substantial scale with a market capitalization of $26.92B and an annual revenue of $9.89B, supported by a workforce of 7,500 employees. These valuation and revenue figures indicate that the company holds a significant position in the pharmaceutical landscape, reflecting its established presence and the substantial resources required to conduct global clinical trials and manage a complex regulatory environment across multiple jurisdictions.
Financial Health
The company reported revenue of $9.89B for the trailing twelve months, generating a net income of $1.29B and an EBITDA of $3.60B. The substantial gap between the $9.89B in revenue and the $1.29B in net income reveals a significant cost structure involving high operating expenses, research and development costs, and administrative overhead typical of large-scale biopharmaceutical operations. Free cash flow stands at $1.98B, which indicates strong financial flexibility allowing the company to fund ongoing R&D programs, return capital to shareholders, or manage debt obligations without immediate dilution. Analyzing the profitability metrics, the gross margin is 78.9%, indicating high pricing power and efficient production of complex biological products; the operating margin is 19.6%, reflecting the scale of overhead costs before interest and taxes; and the profit margin is 13.1%, showing the final percentage of revenue retained as net profit after all expenses. Regarding liquidity and leverage, total cash holdings of $3.82B are lower than total debt of $6.66B, resulting in a debt-to-equity ratio of 36.47, which suggests the balance sheet is moderately leveraged relative to shareholder equity. The current ratio is 2.68, indicating that the company possesses more than double the current assets required to cover its short-term liabilities, demonstrating robust short-term liquidity. Furthermore, the return on equity is 7.4% and the return on assets is 6.1%, metrics that reveal the efficiency with which management utilizes shareholder capital and total assets to generate net income, though these returns are modest compared to historical industry highs.
Valuation Assessment
The trailing twelve-month P/E ratio is 20.87, while the forward P/E is 11.30, a significant difference that implies the market expects earnings to grow substantially in the future to justify the lower forward multiple. The price-to-book ratio is 1.47, indicating that the market values the company at a 47% premium over its net book value, suggesting investors place a higher value on the intangible assets, such as intellectual property and brand equity, than the recorded book value. Alternative valuation metrics include a price-to-sales ratio of 2.72 and an EV/EBITDA of 8.26, which suggest the company is trading at a valuation that balances its cash flow generation against its enterprise value, providing a different perspective than earnings-based multiples. The stock has a 52-week high of $202.41 and a 52-week low of $110.04, and while the exact current price is not listed, the wide range demonstrates significant volatility and potential for price swings based on clinical trial results or regulatory approvals. The beta value is 0.14, which means the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market fluctuations and more driven by company-specific developments.
Growth & Income
Revenue growth year-over-year is -7.1%, while earnings growth for the trailing twelve months is N/A, indicating that the company is currently facing revenue contraction without reported earnings expansion in this specific period. Because earnings growth is listed as N/A rather than a positive percentage, it implies that the company is not currently growing earnings at a faster pace than revenue; in fact, the negative revenue growth suggests the business is under pressure in its core markets or facing headwinds that have impacted top-line performance. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, which implies that management chooses to reinvest all earnings back into the business to fund research, development, and debt reduction rather than paying dividends. The overall growth and income profile is characterized by a period of revenue contraction and a lack of dividend income, requiring investors to evaluate the potential for future recovery in the biopharmaceutical market and the company's ability to restore growth momentum.